Genaera enrolls first patient in phase 2 trial of Evizon in age-related macular degeneration

By Lisa Kerner

Charlotte, N.C., June 26 - Genaera Corp. enrolled the first patient in its multi-center, open-label, pharmacodynamic phase 2 clinical trial, MSI-1256F-212 (Study 212), to evaluate the efficacy and safety of Evizon (squalamine lactate) at higher doses.

Up to 140 patients with wet age-related macular degeneration (AMD) will be treated with Evizon at 40 mg, 80 mg, 120 mg and 160 mg over a 20-week period.

"This study will provide more detailed information on Evizon's effects on visual acuity in both affected eyes of patients with exudative AMD," president and chief executive officer Jack Armstrong said in a company news release.

"There is a significant medical need for a drug that treats wet AMD in both eyes simultaneously, while avoiding the complications of intravitreal injections."

Genaera is a biopharmaceutical company located in Plymouth Meeting, Pa.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.